Oncodona

Early risk detection of hereditary breast and ovarian cancer.

Overview

Oncodona
Benefits
Indications

What is the Oncodona Test?

It is the most advanced genetic test for early identification of predisposition to inherited cancer.

Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.

The presence of a change or mutation in one of these genes assumes that the female carrier has an increased risk of developing breast and ovarian tumours, or other related cancers.

What is the procedure?

[row_inner_3] [col_inner_3 span=”6″ span__sm=”12″]

Why use Oncodona test?

The performance of the test, if positive, can be used to adopt follow-up and personalized early detection measures of the patient and their relatives.
Carriers already diagnosed will be more likely to have another type of cancer.
A positive test result may also have important health implications for family members, and even future generations.

[/col_inner_3] [col_inner_3 span=”6″ span__sm=”12″]

What genes are included in the Oncodona test?

In addition to the BRCA1 and BRCA2 genes, the Oncodona test analyzes 19 more genes associated with risk of breast and ovarian cancer, which makes it a more complete test:

[/col_inner_3] [/row_inner_3]

Who should use Oncodona test?

Women diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test. In these typesof patients Oncodona can find a mutation in up to 4% of women.
Women with a family member diagnosed with breast and ovarian cancer.
Women of general population without known increased risk.

Test limitations

It is reported that, in a particular case, the Oncodona test may not identify a mutation in the genes studied, even though a mutation may actually exist in one of the genes.
It is also reported that the Oncodona test can identify changes for which there is currently no medical consensus as to whether such changes pose an increased risk of developing cancer.
The Oncodona test does not include all genes for which the medical literature indicates a possible association with breast and/or ovarian cancer.

Documentation

Specialists documents

Brochure

Download

Scientific evidence

Relevant related studies:

Malone et al. Cancer Res 2006;66(16):8297-8308

JAMA Oncol. 2015;1(7):943-951. doi:10.1001/jamaoncol. 2015.2690

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility doctors worldwide we investigate human reproduction to change the lives of couples who are trying to conceive.

Learn more about Igenomix

Other services

CGT

Determines the risk of having a child with a genetic disease

More information

PGT-M

Prevents the transmission of single gene disorders

More information

PGT-A

Chromosomally normal
embryos selection

More information

Igenomix is in the media

IGENOMIX has not affiliated any news outlet or publication identified above. News coverage does not constitute an endorsement of IGENOMIX or its products

Mutations in BRCA1 or BRCA2 genes are 20-fold higher in women with precocious breast cancer

Mutations in BRCA1 and BRCA2 account for ≈ 5% of breast cancers and 10-15% of ovarian cancers.

Oncodona test offers genetic counselling by experts

Oncodona analyzes a panel of 21 genes

Are you interested?

Overview

What is the Oncodona Test?

What is the procedure?

Why use Oncodona test?

What genes are included in the Oncodona test?

Who should use Oncodona test?

Test limitations

Documentation

Brochure

Scientific evidence

Relevant related studies:

Can we help you?

Igenomix and fertility

CGT

PGT-M

PGT-A